Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: A randomized controlled trial

James Kahn*, Stephen Lagakos, Michael Wulfsohn, Deborah Cherng, Michael Miller, Julie Cherrington, David Hardy, Gildon Beall, Richard Cooper, Robert Murphy, Nesli Basgoz, Edmund Ng, Steven Deeks, Dean Winslow, John J. Toole, Dion Coakley

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

197 Scopus citations


Context. Adefovir dipivoxil is a nucleotide analog that has demonstrated effective antiretroviral activity against human immunodeficiency virus (HIV) with once-daily administration. Objective. To determine if adefovir confers antiretroviral or immunologic benefit when added to stable antiretroviral therapy. Design. Multicenter, 24-week, randomized, double-blind, placebo- controlled study. Enrollment was conducted from June 3, 1996, through May 6, 1997. Setting. Thirty-three US HIV treatment centers. Participants. Of 1171 patients screened, 442 patients infected with HIV receiving stable antiretroviral therapy for at least 8 weeks with plasma HIV RNA greater than 2500 copies/mL and CD4+ cell count above 0.20 x 109/L were randomized. Intervention. Patients were randomized to receive either a single 120-mg/d dose of adefovir dipivoxil (n = 219) or an indistinguishable placebo (n = 223). All patients received L-carnitine, 500 mg/d. Open-label adefovir was offered after 24 weeks and was continued until the end of the study. Main Outcome Measures. Changes in HIV RNA from baseline, based on area under the curve and CD4+ cell levels, adverse events, and effect of baseline genotypic resistance on response to adefovir. Results. Patients assigned to adefovir demonstrated a 0.4-log10 decline from baseline in HIV RNA compared with no change in the placebo group (P<.001), which continued through 48 weeks. CD4+ cell counts did not change. During the initial 24 weeks, elevated hepatic enzyme levels (P<.001), gastrointestinal tract complaints (P<.001), and weight loss (P<.001) were associated with use of adefovir. Between 24 weeks and 48 weeks elevations in serum creatinine occurred in 60% of patients, usually returning to baseline after discontinuation of adefovir. Patients with lamivudine or lamivudine and zidovudine resistance mutations demonstrated anti-HIV effects with adefovir (P≤.01 vs placebo group). Conclusions. This study suggests that once-daily adefovir therapy reduces HIV RNA and is active against isolates resistant to lamivudine or lamivudine and zidovudine. Nephrotoxicity occurred when treatment extended beyond 24 weeks but was reversible.

Original languageEnglish (US)
Pages (from-to)2305-2312
Number of pages8
Issue number24
StatePublished - Dec 22 1999

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: A randomized controlled trial'. Together they form a unique fingerprint.

Cite this